In this pragmatic , open-label randomised trial , patients newly diagnosed with Parkinson 's disease were randomly assigned ( by telephone call to a central office ; 1:1:1 ) between levodopa-sparing therapy ( dopamine agonists or MAOBI ) and levodopa alone .